Valneva SE (VALN)

[p0]

Investor Conferences in the United States and Europe

Saint-Herblain (France), August 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its senior leadership team are scheduled to participate in 1-on-1 meetings with institutional investors at the following investor conferences in September 2023.

The Company will discuss its single-dose vaccine candidate against the chikungunya virus (VLA1553), currently under priority review by the U.S. FDA with a Prescription Drug User Fee Act (PDUFA) action date planned for end of November 2023[1], as well as its Lyme disease vaccine candidate (VLA15), which is currently in Phase 3 clinical trials led by Valneva’s development partner Pfizer. The Company will also discuss its existing commercial vaccine portfolio, which has been resuming strong revenue growth since the lifting of the COVID-19 travel restrictions.

Additionally, the Company will hold a live conference call and webcast for its first half 2023 financial results on Thursday September 21, 2023, at 3 p.m. CEST / 9 a.m. EDT. Please refer to the following links.



Morgan Stanley 21st Annual Global Healthcare Conference

Date: Monday, September 11, 2023

Location: New York, NY



Kepler Cheuvreux Autumn Conference 2023

Date: Tuesday, September 12, 2023

Location: Paris, France



H.C. Wainwright 25th Annual Global Investment Conference

Date: September 12-13, 2023

Location: New York, NY



To request a meeting, please contact your representative at the respective hosting banks.

https://valneva.com/press-release/valneva-to-participate-in-investor-conferences-in-the-united-states-and-europe-in-september-2023/